# OnCo record hyperphosphataemia-on-fgfr-inhibitors (protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/protocols/hyperphosphataemia-on-fgfr-inhibitors/>
  a schema:MedicalGuideline ;
  onco:kind "protocol" ;
  schema:identifier "hyperphosphataemia-on-fgfr-inhibitors" ;
  schema:name "High phosphate on FGFR inhibitors (erdafitinib, pemigatinib, futibatinib): monitoring, diet, binders and dose rules"@en ;
  schema:alternateName "erdafitinib hyperphosphataemia"@en, "pemigatinib hyperphosphataemia"@en, "futibatinib hyperphosphataemia"@en, "FGFR inhibitor hyperphosphatemia"@en, "high phosphate on Balversa"@en, "high phosphate on Pemazyre"@en, "high phosphate on Lytgobi"@en, "low phosphate diet on FGFR inhibitors"@en, "phosphate binders with FGFR inhibitors"@en ;
  schema:description "Erdafitinib, pemigatinib and futibatinib raise blood phosphate in most people, usually in the first weeks. Phosphate is checked with blood tests. A rise is treated with a low-phosphate diet, tablets taken with food that bind phosphate, and sometimes a pause or a lower dose. Report cramps, tingling round the mouth or painful skin lumps. Your own team's plan comes first."@en ;
  schema:url <https://onco.cc/protocols/hyperphosphataemia-on-fgfr-inhibitors/> ;
  schema:dateModified "2026-11-17"^^xsd:date ;
  onco:targets <https://onco.cc/targets/fgfr1/>, <https://onco.cc/targets/fgfr2/> ;
  onco:drugs <https://onco.cc/drugs/erdafitinib/>, <https://onco.cc/drugs/pemigatinib/>, <https://onco.cc/drugs/futibatinib/> ;
  onco:pathways <https://onco.cc/pathways/fgfr-signalling/> .
